https://www.pharmaradar360.com/article/9164e8a3ea4188d8PharmaRadar360en2026-04-11T00:00:00.000ZPharma Research & Developmenthttps://www.pharmaradar360.com/article/a6d04440b8d67e7bPharmaRadar360en2026-04-11T00:00:00.000ZLatest Researchhttps://www.pharmaradar360.com/article/19f59684ccd74cc6PharmaRadar360en2026-04-11T00:00:00.000ZGeliose Mobility, an IIT Delhi incubated startup, launches ‘HOPE’, an affordable electric scooter for last mile delivery and personal commutehttps://www.pharmaradar360.com/article/2f248d6ce8bb4cebPharmaRadar360en2026-04-10T21:04:26.000ZAllogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 202https://www.pharmaradar360.com/article/98bd3f68fba7139fPharmaRadar360en2026-04-10T20:53:38.000ZPredicting T Cell Recognition: New Insights from Large-Scale Activation Datahttps://www.pharmaradar360.com/article/cd5efb6e2cb34c46PharmaRadar360en2026-04-10T20:00:36.000ZGAP Nail™ Endo-Exo Medullary Systemhttps://www.pharmaradar360.com/article/830b8ec3b42c913fPharmaRadar360en2026-04-10T16:00:00.000ZDecision: Advertising investigations: March 2026https://www.pharmaradar360.com/article/c66db7daf1cc0ecfPharmaRadar360en2026-04-10T16:00:00.000ZKennedy expands ACIP function, membership criteriahttps://www.pharmaradar360.com/article/5b715e12d81ebb52PharmaRadar360en2026-04-10T15:30:00.000Z日本新薬とイクスフォレストセラピューティクス RNA構造を標的とした創薬研究に関する契約を締結https://www.pharmaradar360.com/article/d9b6e6f4728831a0PharmaRadar360en2026-04-10T15:08:25.000ZVirtual Twins: What They Are & Their Impact in Life Scienceshttps://www.pharmaradar360.com/article/111274929215e1bbPharmaRadar360en2026-04-10T14:00:00.000ZMeeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 April 2026https://www.pharmaradar360.com/article/4d9ceb5c4c37ee01PharmaRadar360en2026-04-10T12:35:30.000ZeXoZymes CCO, Damien Perriman, outlines NCTx strategy and the commercial path for cell-free biomanufacturing on Grow Everything podcasthttps://www.pharmaradar360.com/article/7a216e651106fb9bPharmaRadar360en2026-04-10T12:29:45.000ZANMAT concluyó el proceso para la baja definitiva de las firmas HLB PHARMA GROUP S.A. y LABORATORIOS RAMALLO S.A.https://www.pharmaradar360.com/article/3c0f8e692dacdbe3PharmaRadar360en2026-04-10T10:00:00.000ZTislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)https://www.pharmaradar360.com/article/e166fe404610756cPharmaRadar360en2026-04-10T08:00:00.000Z「デジタルトランスフォーメーション銘柄（DX銘柄）2026」選定のお知らせhttps://www.pharmaradar360.com/article/f926d17dcb34b0faPharmaRadar360en2026-04-10T08:00:00.000ZChugai Selected as “Digital Transformation Stocks (DX Stocks) 2026&rdquohttps://www.pharmaradar360.com/article/4ffded644d4b86c0PharmaRadar360en2026-04-10T07:00:00.000ZA Clínic-IDIBAPS study discovers that nanoparticles with DNA enhance the effect of immunotherapy against cancer